Novartis enlisted the help of Danish drug discovery company Nuevolution to identify small molecule leads against specific drug targets. Nuevolution will use its fragment-based drug screening platform called Chemetics®. The company says this technology combines proven wet chemistry and molecular biology to allow the rapid synthesis and selection of ligands from potentially billions of drug-like compounds in a single test tube.  The companies will work together to carry out hit-to-lead optimization.


 

Previous articleGeron’s Setback with Testing Its hESC Therapy in Humans Points to FDA’s Continued Cautionary Stance
Next articleAcadia Crashes with Negative Results from Phase III Antipsychosis Candidate